The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.
Mitsukuni Suenaga
No relevant relationships to disclose
Satoshi Matsusaka
No relevant relationships to disclose
Nobuyuki Mizunuma
No relevant relationships to disclose
Eiji Shinozaki
No relevant relationships to disclose
Mariko Ogura
No relevant relationships to disclose
Masato Ozaka
No relevant relationships to disclose
Koichi Takagi
No relevant relationships to disclose
Toshiharu Yamaguchi
No relevant relationships to disclose
Kiyohiko Hatake
No relevant relationships to disclose